1. Home
  2. HAE vs ICUI Comparison

HAE vs ICUI Comparison

Compare HAE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HAE
  • ICUI
  • Stock Information
  • Founded
  • HAE 1971
  • ICUI 1984
  • Country
  • HAE United States
  • ICUI United States
  • Employees
  • HAE N/A
  • ICUI N/A
  • Industry
  • HAE Medical/Dental Instruments
  • ICUI Medical/Dental Instruments
  • Sector
  • HAE Health Care
  • ICUI Health Care
  • Exchange
  • HAE Nasdaq
  • ICUI Nasdaq
  • Market Cap
  • HAE 3.3B
  • ICUI 3.4B
  • IPO Year
  • HAE 1991
  • ICUI 1992
  • Fundamental
  • Price
  • HAE $67.46
  • ICUI $132.10
  • Analyst Decision
  • HAE Strong Buy
  • ICUI Strong Buy
  • Analyst Count
  • HAE 9
  • ICUI 5
  • Target Price
  • HAE $99.78
  • ICUI $196.75
  • AVG Volume (30 Days)
  • HAE 578.9K
  • ICUI 283.6K
  • Earning Date
  • HAE 05-08-2025
  • ICUI 05-08-2025
  • Dividend Yield
  • HAE N/A
  • ICUI N/A
  • EPS Growth
  • HAE 44.54
  • ICUI N/A
  • EPS
  • HAE 3.31
  • ICUI N/A
  • Revenue
  • HAE $1,360,824,000.00
  • ICUI $2,420,093,000.00
  • Revenue This Year
  • HAE N/A
  • ICUI N/A
  • Revenue Next Year
  • HAE $6.76
  • ICUI N/A
  • P/E Ratio
  • HAE $20.46
  • ICUI N/A
  • Revenue Growth
  • HAE 3.96
  • ICUI 7.22
  • 52 Week Low
  • HAE $55.30
  • ICUI $101.44
  • 52 Week High
  • HAE $94.99
  • ICUI $196.26
  • Technical
  • Relative Strength Index (RSI)
  • HAE 54.87
  • ICUI 45.23
  • Support Level
  • HAE $66.42
  • ICUI $127.91
  • Resistance Level
  • HAE $68.75
  • ICUI $135.62
  • Average True Range (ATR)
  • HAE 1.30
  • ICUI 4.22
  • MACD
  • HAE -0.26
  • ICUI -0.20
  • Stochastic Oscillator
  • HAE 45.00
  • ICUI 23.47

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Share on Social Networks: